The present status and problems of multi-target therapy of myasthenia gravis
10.3760/cma.j.issn.1006-7876.2018.12.001
- VernacularTitle:重症肌无力多靶点治疗的现状和问题
- Author:
Chongbo ZHAO
1
;
Sushan LUO
Author Information
1. 复旦大学附属华山医院神经内科
- Keywords:
Myasthenia gravis;
Neuromuscular junction;
Acetylcholine;
Multi-target therapy
- From:
Chinese Journal of Neurology
2018;51(12):937-941
- CountryChina
- Language:Chinese
-
Abstract:
The clinical manifestation of myasthenia gravis is due to the acetylcholine transmission defect of neuromuscular junction caused by autoimmune disturbance. With the intensive understanding of the pathogenesis and the emerging of specific immunological targeting therapy, therapeutic investigations are widely expanding. A multi-target therapy pattern is now available based on treatments primed to distinct immunopathological processes and improving neuromuscular junction transmission. We will comment the status and problems in this article.
